Prelims: Current events of national and international importance | Environment
Why in News?
Recently, scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, developed India-specific disease severity scoring models—ISS1 and ISS2 (India-specific Severity Score).
- It aims to accurately predict clinical outcomes and manage treatment in Indian patients with Sickle Cell Anaemia (SCA).
- It addresses a critical void, standard international scoring models like the Paediatric Severity Score (PSS) failed to reflect the true clinical progression of Indian patients.
The Need for an India-Specific Model
- Indian SCA patients often display a distinct clinical profile compared to African and Western populations.
- They generally possess higher baseline levels of fetal hemoglobin (HbF), which tempers disease severity.
- Complications predominant in African populations such as priapism, leg ulcers, and severe pulmonary hypertension are relatively rare in India.
- Conversely, severe anemia, recurrent blood transfusions, painful vaso-occlusive crises, and acute febrile illnesses driven by nutritional deficiencies and endemic tropical infections dominate Indian clinical cases.
- The standard international Paediatric Severity Score (PSS) achieved only ~67% concordance with expert clinical assessments in Indian settings.
Key Features: ISS1 and ISS2 Models
|
Feature / Model
|
ISS1 (Modified Clinical Model)
|
ISS2 (Simplified Clinical Model)
|
|
Accuracy / Concordance
|
Reached ~83% concordance with expert pediatric evaluation.
|
Achieved ~85% concordance and correctly identified 100% of mild cases.
|
|
Core Innovation
|
Integrates clinical indicators prevalent in Indian patients (frequent transfusions, severe anemia, acute febrile episodes).
|
Relies on easily observable bedside clinical indicators rather than complex, high-cost laboratory diagnostics.
|
|
Primary Utility
|
Facilitates nuanced clinical stratification for secondary/tertiary hospitals.
|
Designed for resource-constrained primary healthcare centers (PHCs) to quickly triage patients.
|
Significance
- Targeted Drug Dosage -Helps clinicians determine early, tailored administration and exact dosages of Hydroxyurea, a essential drug that elevates HbF levels and prevents painful vaso-occlusive crises.
- Support for National Sickle Cell Anaemia Elimination Mission (2023–2047)- Directly supports India's mission to eliminate sickle cell disease by 2047 through early screening, risk-stratification, and targeted management across tribal belts.
- Decoupling from Expensive Diagnostics- ISS2 enables rural healthcare providers to stratify risk without requiring specialized molecular or expensive biochemical laboratory setups.
Reference
The Hindu | India-specific tool to predict Sickle Cell severity
